⚠ Data freshness notice: the most recent refresh of NHTSA was incomplete, so a
very recent recall may be missing. Everything shown is accurate as of the last checked time on this page —
for anything time-critical, confirm with the official sources linked below.
FDAClass II · Drug · Recalled July 15, 2026
Pemetrexed for Injection 500mg/Vial recall — Reliance Life Sciences Private Limited
Hazard: Lack of Sterility Assurance
Class II: may cause temporary or medically reversible health consequences.
View the official FDA enforcement record (openFDA) ↗
- Official recall ID
- D-0672-2026
- Brand
- Reliance Life Sciences Private
- Classification
- Class II
- Units affected
- 5,020 vials
- Recall status
- Ongoing
- Initiated
- Voluntary: Firm initiated
Description
Pemetrexed for Injection 500mg/Vial, 1 50 mL Single-Dose Vial per carton, For intravenous use only, Rx only, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873 NDC: 70069-0835-01
Affected products
Companies & origin
- Recalling firm location
- Navi Mumbai, N/A, India
- Firm address
- Ttc Area Of Midc, R - 282 Dhirubhai Ambani Life Sciences Centre; Thane Belapur Road, N/A
Identifying details (verbatim from the notice)
- Product codes / lots
- Lot, expiry: RPTH0125A Jan 31, 2028; RPTH0225A Jan 31, 2028; RPTH0325A Jan 31, 2028; RPTH0725A Apr 30, 2028;
- Distribution
- Nationwide in the USA
- Firm notified the public via
- Letter
- FDA event ID
- 99312
- Recall initiated
- June 24, 2026
- FDA classified
- July 8, 2026
- FDA report date
- July 15, 2026
Source: U.S. Food & Drug Administration. This page mirrors the official public-domain record verbatim;
the linked government source is authoritative. Source last checked July 23, 2026 at 11:04 PM UTC.
Report a data error on this page